 |
|
Is Leflunomide Effective in the Treatment of Psoriasis in a Patient Who Is Unable to Benefit From Standard First- and Second-Line Therapies and Needs an Affordable Treatment Option?
Andrew Graeme Affleck, BSc(Hons), MB, ChB;
Hywel Williams, MSc, PhD, FRCP
Arch Dermatol. 2008;144(12):1642-1643.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
INTRODUCTION
Clinical Question: Is leflunomide effective in the treatment of psoriasis in a patient who is unable to benefit from standard first- and second-line therapies and needs an affordable treatment option?
Background
A 21-year-old man was seen for a 4-year history of recalcitrant, severe psoriasis. The problem affected the patient's quality of life significantly, especially in having to miss lectures at college. Many treatments had been tried. He had been admitted to the hospital 4 times and was a regular attendee at the day treatment unit. Topical coal tar and anthralin caused irritation. Acitretin therapy (0.5 mg/kg) was ineffective. Therapy with oral or intramuscular methotrexate caused intolerable nausea. Systemic psoralen–UV-A and narrowband UV-B caused repeated erythema and were therefore stopped. Cyclosporin therapy caused acute renal impairment.
Leflunomide is a disease-modifying antirheumatic drug recently licensed for psoriatic arthritis, for which it has . . . [Full Text of this Article]
Literature Search
Appraisal of the Evidence
Comment
Limitations of the Critically Appraised Topic
Clinical Bottom Line
What Happened to Our Patient?
Departments of Dermatology, Ninewells Hospital and Medical School, Dundee, Scotland (Dr Affleck), and Queen's Medical Centre, Nottingham University Hospitals NHS Trust, Nottingham, England (Dr Williams)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
